Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The goals of this study are to study MMFS-202-302 in a double blind, randomized, placebo-controlled 9-week study of its effect on ameliorating cognitive deficits in 60 patients with schizophrenia or schizoaffective disorder with stable levels of positive symptoms. Secondary end points will include changes in positive and negative symptoms. One dose of MMFS-202-302 will be studied and compared with placebo as adjunctive treatment to atypical antipsychotic drug treatment.
Epistemonikos ID: cf1d58599785fe75e58265b316199ccd36199d0c
First added on: May 12, 2024